Robsahm TE, Tsuruda KM, Hektoen HH, Storås AH, Cook MB, Hurwitz LM, Langseth H (2023)
Applying recommended definition of aggressive prostate cancer: a validation study using high-quality data from the Cancer Registry of Norway
Acta Oncol, 62 (1), 8-14
DOI 10.1080/0284186X.2023.2175331, PubMed 36762472

Lilleby W, Seierstad T, Inderberg EM, Hole KH (2023)
Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring
Int J Cancer, 152 (10), 2166-2173
DOI 10.1002/ijc.34448, PubMed 36715014

Møller CT, Støer NC, Blindheim A, Berge V, Tafjord G, Fosså SD, Andreassen BK (2022)
Downstaging and survival after Neoadjuvant chemotherapy for bladder cancer in Norway; a population-based study
BMC Cancer, 22 (1), 1301
DOI 10.1186/s12885-022-10394-w, PubMed 36510166